At least one of the UK's biotech companies is home and dry. Much of the sector is paying a high price for failing to raise enough cash during the biotech boom, and remains stubbornly resistant to consolidation. (See "UK Biotech Learns the Hard Way," START-UP, March 2002 Also see "UK Biotech Learns the Hard Way" - Scrip, 1 March, 2002..)
Cancer company Antisoma PLC was no exception. To avoid dilution, it only raised top-up funding of £8.7 million ($13.7 million) in 2000 [See Deal], hoping that milestone payments...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?